Loading
MYTX-011 is an experimental antibody-drug conjugate from Mythic Therapeutics, in phase 1 trials for non-small cell lung cancer; its current status is not stated.
MYTX-011 is an antibody-drug conjugate (cMET-targeted, MMAE payload, DAR 2) from Mythic Therapeutics. An antibody-drug conjugate targeting cMET (MET) carrying MMAE at a drug-to-antibody ratio of 2, engineered on the FateControl platform. Its furthest stage is phase 1, for non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. KisMET-01 (NCT05652868) terminated for 'Business decision' (completion Nov 2025); Mythic made an assignment for the benefit of creditors on 21 Nov 2025 and the assets were offered for sale (bid deadline 5 Jan 2026). Buyer not known. Whether it works in people has not been established unless a trial below reports it.
An antibody-drug conjugate targeting cMET (MET) carrying MMAE at a drug-to-antibody ratio of 2, engineered on the FateControl platform. Connects to MET.
1.MYTX-011's antibody arm binds MET on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MYTX-011" OR ABSTRACT:"MYTX-011") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MYTX-011, not a curated reading list.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET and the tag pipeline.
Shares MET and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET, Non-small-cell lung cancer and the tag pipeline.
Shares MET and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/